In a prospective multicenter trial, Jourdan et al.16 demonstrated, by RQ-PCR, that a less than 3-log MRD reduction of RUNX1-RUNX1T1 transcript after the first consolidation was associated with a higher specific hazard of relapse in young CBF-AML patients. Here, RUNX1 is linked to acute myeloid leukemia.